Pharmaceuticals, Biotechnology and Life Sciences
Sundial Brands, a skincare and haircare manufacturer has launched its first skincare line – nyakio. Nyakio Kamoche Grieco, a first-generation American of Kenyan descent, partnered with Sundial Brands to bring her family’s recipes to the U.S. market.
Novartis’s division Sandoz has reported that Phase 3 confirmatory efficacy, safety and immunogenicity study met its primary endpoint demonstrating biosimilar adalimumab GP2017 has equivalent efficacy to the reference medicine, Humira.
The study “Mechanisms, Pathophysiology, and Management of Obesity” underscores the key elements of treating obesity which include live counseling, a low-calorie diet, physical activity and behavior modification – all of which are fundamental elements of the weight loss program.
XW Laboratories has partnered up with the University of Pittsburgh on commercialization of certain compounds based on pioneering mitochondria targeted bis-nitroxide technology developed in the laboratory of Professor Peter Wipf.
TiGenix has received the Day 180 List of Outstanding Issues (LoOI) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and expects to receive a Marketing Authorization decision for Crohn’s disease drug Cx601 in 2017.
CTI BioPharma has reported neto loss of $6.4 million for the fourth quarter 2016. Net loss has decreased comparing the same period last year when the company reported net loss of $28.8 million. As for the full year, the company has reported net loss of $52.0 million, which is also decrease comparing last years loss of $122.6 million.
ALK has named Hendrik Nolte new R&D strategist in North America and International markets including China, and will work in collaboration with ALK’s partners for Russia, Japan, South-East Asia, Australia and New Zealand, Denmark-headquartered company said Friday.
Sanofi’s vaccines global business unit Sanofi Pasteur has signed a deal with AstraZeneca’s biologics bramch MedImmune, to make and sell a monoclonal antibody-called MEDI8897-for the prevention of the most common reason for lower respiratory tract infections in newborns and infants, Respiratory Syncytial Virus (RSV).
Leonard Bell, founder of Alexion Pharmaceuticals will not stand for reelection as a Board member and will retire as Chairman of the Board and as a Director at the end of his term, effective as of the Annual Meeting of Shareholders scheduled for May 10, 2017.
In our quest for beautiful hair, we often do things that damage our hair. Damaged hair is fragile, so it tends to break. Hair breakage can leave us with frizzy, unhealthy looking hair. If we continue to damage our hair, we may eventually see thinning hair or even bald spots.